BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

Kelun-Biotech and Harbour BioMed Ink $970 Million Licensing Deal with Windward Bio for Anti-TSLP Antibody

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (togeth...

January 13, 2025 | News

Global Frenzy for TCE Bispecific Antibodies: Billion-Dollar Deals Propel Chinese Biotech to the Forefront

The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantical...

January 10, 2025 | News

Samsung Biologics and LigaChem Biosciences Partner to Advance ADC Therapies with New Dedicated Facility

Samsung Biologics to offer ADC services at new dedicated facility Extended collaboration reflects successful partnership and expertise Samsung Biolog...

January 09, 2025 | News

Biocytogen and Acepodia Join Forces to Advance Precision Oncology with Dual-Payload Bispecific ADCs

Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs) Biocytogen’s RenLite® meets Acepodia’s...

January 08, 2025 | News

Radiopharm and Lantheus Join Forces to Advance Radiopharmaceutical Clinical Development in Australia

RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging t...

December 31, 2024 | News

BeiGene Exercises Exclusive Option for DualityBio's B7H4 ADC, Paving the Way for Global Development

Duality Biologics ("DualityBio") announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C907...

December 31, 2024 | News

Alphamab Oncology Gains Approval for Phase III Clinical Study of Anti-HER2 ADC JSKN003 in Platinum-Resistant Ovarian Cancer

Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for...

December 30, 2024 | News

Porton Pharma and Dragon Sail Pharmaceutical Forge Strategic Alliance to Advance ADC Drug Development

Porton Pharma Solutions (hereinafter referred to as "company" or "Porton") and Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. (a subsidiary of Guilin Sanj...

December 24, 2024 | News

Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025

Antibody-Drug Conjugates (ADCs) represent a paradigm shift in oncology, offering targeted cancer treatment that minimizes collateral damage to healthy cell...

December 23, 2024 | News

Sanofi and SK Bioscience Forge Expanded Alliance to Combat Pneumococcal Disease with Next-Gen Vaccines

Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine ...

December 23, 2024 | News

CStone Pharmaceuticals Submits Clinical Trial Application in Australia for CS2009, a Tri-Specific Antibody Targeting Solid Tumors

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therap...

December 23, 2024 | News

OmniAb Showcases Multispecific Antibody Workflow and Launches OmniHub™ at AETC 2024

Presentations included a case study of the workflow for building multispecifics and the launch of OmniHub™, a bioinformatics tools platform ...

December 17, 2024 | News

SK Biopharmaceuticals and ProEn Therapeutics to Develop Two Radiopharmaceutical Candidates by 2027 Using ArtBody™ Platform

SK Biopharmaceuticals, ProEn Therapeutics aim to advance up to 2 preclinical radiopharmaceutical candidates by 2027, via ArtBody™, a bivalent binder ...

December 17, 2024 | News

Porton Pharma Solutions and Aojin Life Sciences Forge Strategic Partnership to Advance XDC Conjugate Drug Development

Porton Pharma Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences"). Porton will...

December 13, 2024 | News

Stay Connected